Search

Your search keyword '"Elia, Gabriella"' showing total 415 results
Start Over Author "Elia, Gabriella"
415 results on '"Elia, Gabriella"'

3. Investigating the genetic diversity of CRESS DNA viruses in cats identifies a novel feline circovirus and unveils exposure of cats to canine circovirus

Author

Vasinioti, Violetta Iris, Pellegrini, Francesco, Buonavoglia, Alessio, Capozza, Paolo, Cardone, Roberta, Diakoudi, Georgia, Desario, Costantina, Catella, Cristiana, Vicenza, Teresa, Lucente, Maria Stella, Di Martino, Barbara, Camero, Michele, Elia, Gabriella, Decaro, Nicola, Martella, Vito, and Lanave, Gianvito

Published
2023
Full Text
View/download PDF

4. Oxfam Fresh Food Voucher Programme: Rohingya refugee response in Cox’s Bazar, Bangladesh, January 2018 – September 2019

Author

D’Elia, Gabriella and Akhtar Jahan Rume, Khodeza

Subjects
Approach and methodology, Humanitarian
Abstract

In response to the rapid influx of Rohingya refugees in Cox’s Bazar, south-east Bangladesh, Oxfam implemented a Fresh Food Voucher (FFV) programme in August 2017. Vouchers were distributed on a monthly basis from January 2018 to August 2019, with funding from ECHO and the DEC. The intervention aimed to ensure dignified access to a wide range of fresh food for vulnerable and food-insecure refugee households and to improve their nutritional status. The programme also aimed to support the local economy by making goods available from local market vendors, who sourced produce locally where possible., This report presents the key findings of the evaluation of the initiative, with lessons and recommendations. It is hoped that this will prove useful for agencies using voucher programming in the Rohingya response and elsewhere. It is also a contribution to the wider influencing agenda around market-based programming, including cash and vouchers.

Published
2020
Full Text
View/download PDF

5. A novel hepadnavirus in domestic dogs

Author

Diakoudi, Georgia, Capozza, Paolo, Lanave, Gianvito, Pellegrini, Francesco, Di Martino, Barbara, Elia, Gabriella, Decaro, Nicola, Camero, Michele, Ghergo, Paola, Stasi, Fabio, Cavalli, Alessandra, Tempesta, Maria, Barrs, Vanessa R., Beatty, Julia, Bányai, Krisztián, Catella, Cristiana, Lucente, Maria S., Buonavoglia, Alessio, Fusco, Giovanna, and Martella, Vito

Published
2022
Full Text
View/download PDF

7. Possible Human-to-Dog Transmission of SARS-CoV-2, Italy, 2020

Author

Decaro, Nicola, Vaccari, Gabriele, Lorusso, Alessio, Lorusso, Eleonora, De Sabato, Luca, Patterson, Edward I., Bartolo, Ilaria Di, Hughes, Grant L., Teodori, Liana, Desario, Costantina, Colitti, Barbara, Ricci, Dominga, Buonavoglia, Domenico, Rosati, Sergio, Martella, Vito, Camma, Cesare, Agrimi, Umberto, and Elia, Gabriella

Subjects
Dogs -- Health aspects, Disease transmission -- Risk factors, Dog owners -- Health aspects, Health
Abstract

Coronavirus disease (COVID-19), caused by infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), emerged in humans in Wuhan, China, in late December 2019, probably because of spillover from an [...]

Published
2021

8. Genetic characterization of parvoviruses identified in stray cats in Nigeria

Author

Oluwayelu, Daniel Oladimeji, primary, Desario, Costantina, additional, Babalola, Eunice Temilade, additional, Pratelli, Annamaria, additional, Daodu, Oluwafemi Babatunde, additional, Elia, Gabriella, additional, Odemuyiwa, Solomon Olawole, additional, Buonavoglia, Canio, additional, Decaro, Nicola, additional, and Diakoudi, Georgia, additional

Published
2023
Full Text
View/download PDF

11. Hepadnavirus Infection in a Cat with Chronic Liver Disease: A Multi-Disciplinary Diagnostic Approach

Author

Capozza, Paolo, primary, Pellegrini, Francesco, additional, Camero, Michele, additional, Diakoudi, Georgia, additional, Omar, Ahmed Hassan, additional, Salvaggiulo, Anna, additional, Decaro, Nicola, additional, Elia, Gabriella, additional, Catucci, Leonardo, additional, Di Martino, Barbara, additional, Fruci, Paola, additional, Tomassini, Letizia, additional, Lepri, Elvio, additional, Martella, Vito, additional, and Lanave, Gianvito, additional

Published
2023
Full Text
View/download PDF

13. Novel Orthopoxvirus and Lethal Disease in Cat, Italy

Author

Lanave, Gianvito, Dowgier, Giulia, Decaro, Nicola, Albanese, Francesco, Brogi, Elisa, Parisi, Antonio, Losurdo, Michele, Lavazza, Antonio, Martella, Vito, Buonavoglia, Canio, and Elia, Gabriella

Subjects
Genes -- Health aspects, Infection -- Genetic aspects -- Health aspects, Skin -- Health aspects, Phylogeny -- Health aspects, Genomes -- Health aspects, Genomics -- Health aspects, Health
Abstract

Orthopoxviruses (OPXVs; family Poxviridae, subfamily Chordopoxvirinae, genus Orthopoxvirus) are complex, double-stranded DNA viruses with ongoing interest because of their potential use as bioterrorism agents and in gene therapy. Variola virus [...]

Published
2018
Full Text
View/download PDF

16. Use of a commercial feed supplement based on yeast products and microalgae with or without nucleotide addition in calves

Author

Maggiolino, Aristide, primary, Centoducati, Gerardo, additional, Casalino, Elisabetta, additional, Elia, Gabriella, additional, Latronico, Tiziana, additional, Liuzzi, Maria Grazia, additional, Macchia, Luigi, additional, Dahl, Geoffrey E., additional, Ventriglia, Gianluca, additional, Zizzo, Nicola, additional, and De Palo, Pasquale, additional

Published
2023
Full Text
View/download PDF

17. A Cold Case of Equine Influenza Disentangled with Nanopore Sequencing

Author

Pellegrini, Francesco, primary, Buonavoglia, Alessio, additional, Omar, Ahmed H., additional, Diakoudi, Georgia, additional, Lucente, Maria S., additional, Odigie, Amienwanlen E., additional, Sposato, Alessio, additional, Augelli, Raffaella, additional, Camero, Michele, additional, Decaro, Nicola, additional, Elia, Gabriella, additional, Bányai, Krisztián, additional, Martella, Vito, additional, and Lanave, Gianvito, additional

Published
2023
Full Text
View/download PDF

18. Detection of Selected Canine Viruses in Nigerian Free-Ranging Dogs Traded for Meat Consumption

Author

Ndiana, Linda A., primary, Lanave, Gianvito, additional, Desario, Costantina, additional, Odigie, Amienwanlen E., additional, Madubuike, Kelechi G., additional, Lucente, Maria Stella, additional, Ezeifeka, Chukwuemeka A., additional, Patruno, Giovanni, additional, Lorusso, Eleonora, additional, Elia, Gabriella, additional, Buonavoglia, Canio, additional, and Decaro, Nicola, additional

Published
2023
Full Text
View/download PDF

25. Deconstructing SARS‐CoV‐2 neutralization: A modular molecular framework for computational design and comparison of antibodies and nanobodies targeting the spike RBD.

Author

Tragni, Vincenzo, Mercurio, Ivan, Paoletti, Diletta Pia, Onofrio, Angelo, Laera, Luna, Cafferati Beltrame, Lucas, Sgobba, Maria Noemi, Guerra, Lorenzo, Volpicella, Mariateresa, De Grassi, Anna, Elia, Gabriella, and Pierri, Ciro Leonardo

Subjects
SARS-CoV-2, IMMUNOGLOBULINS
Abstract

Since 2020 the COVID‐19 pandemic has led scientists to search for strategies to predict the transmissibility and virulence of new severe acute respiratory syndrome coronavirus 2 variants based on the estimation of the affinity of the spike receptor binding domain (RBD) for the human angiotensin‐converting enzyme 2 (ACE2) receptor and/or neutralizing antibodies. In this context, our lab developed a computational pipeline to quickly quantify the free energy of interaction at the spike RBD/ACE2 protein–protein interface, reflecting the incidence trend observed in the transmissibility/virulence of the investigated variants. In this new study, we used our pipeline to estimate the free energy of interaction between the RBD from 10 variants, and 14 antibodies (ab), or 5 nanobodies (nb), highlighting the RBD regions preferentially targeted by the investigated ab/nb. Our structural comparative analysis and interaction energy calculations allowed us to propose the most promising RBD regions to be targeted by future ab/nb to be designed by site‐directed mutagenesis of existing high‐affinity ab/nb, to increase their affinity for the target RBD region, for preventing spike‐RBD/ACE2 interactions and virus entry in host cells. Furthermore, we evaluated the ability of the investigated ab/nb to simultaneously interact with the three RBD located on the surface of the trimeric spike protein, which can alternatively be in up‐ or down‐ (all‐3‐up‐, all‐3‐down‐, 1‐up‐/2‐down‐, 2‐up‐/1‐down‐) conformations. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

27. Evaluation of Novel Guanidino-Containing Isonipecotamide Inhibitors of Blood Coagulation Factors against SARS-CoV-2 Virus Infection

Author

De Maio, Flavio, primary, Rullo, Mariagrazia, additional, de Candia, Modesto, additional, Purgatorio, Rosa, additional, Lopopolo, Gianfranco, additional, Santarelli, Giulia, additional, Palmieri, Valentina, additional, Papi, Massimiliano, additional, Elia, Gabriella, additional, De Candia, Erica, additional, Sanguinetti, Maurizio, additional, and Altomare, Cosimo, additional

Published
2022
Full Text
View/download PDF

28. Diversity of CRESS DNA Viruses in Squamates Recapitulates Hosts Dietary and Environmental Sources of Exposure

Author

Capozza, Paolo, primary, Lanave, Gianvito, additional, Diakoudi, Georgia, additional, Pellegrini, Francesco, additional, Cardone, Roberta, additional, Vasinioti, Violetta Iris, additional, Decaro, Nicola, additional, Elia, Gabriella, additional, Catella, Cristiana, additional, Alberti, Alberto, additional, Bányai, Krisztián, additional, Mendoza-Roldan, Jairo Alfonso, additional, Otranto, Domenico, additional, Buonavoglia, Canio, additional, and Martella, Vito, additional

Published
2022
Full Text
View/download PDF

29. Evaluation of Novel Guanidino-Containing Isonipecotamide Inhibitors of Blood Coagulation Factors against SARS-CoV-2 Virus Infection

Author

De Maio, Flavio, Rullo, Mariagrazia, de Candia, Modesto, Purgatorio, Rosa, Lopopolo, Gianfranco, Santarelli, Giulia, Palmieri, Valentina, Papi, Massimiliano, Elia, Gabriella, De Candia, Erica, Sanguinetti, Maurizio, Altomare, Cosimo Damiano, Papi, Massimiliano (ORCID:0000-0002-0029-1309), De Candia, Erica (ORCID:0000-0003-0942-2819), Sanguinetti, Maurizio (ORCID:0000-0002-9780-7059), De Maio, Flavio, Rullo, Mariagrazia, de Candia, Modesto, Purgatorio, Rosa, Lopopolo, Gianfranco, Santarelli, Giulia, Palmieri, Valentina, Papi, Massimiliano, Elia, Gabriella, De Candia, Erica, Sanguinetti, Maurizio, Altomare, Cosimo Damiano, Papi, Massimiliano (ORCID:0000-0002-0029-1309), De Candia, Erica (ORCID:0000-0003-0942-2819), and Sanguinetti, Maurizio (ORCID:0000-0002-9780-7059)

Abstract

Coagulation factor Xa (fXa) and thrombin (thr) are widely expressed in pulmonary tissues, where they may catalyze, together with the transmembrane serine protease 2 (TMPRSS2), the coronaviruses spike protein (SP) cleavage and activation, thus enhancing the SP binding to ACE2 and cell infection. In this study, we evaluate in vitro the ability of approved (i.e., dabigatran and rivaroxaban) and newly synthesized isonipecotamide-based reversible inhibitors of fXa/thr (cmpds 1-3) to hinder the SARS-CoV-2 infectivity of VERO cells. Nafamostat, which is a guanidine/amidine antithrombin and antiplasmin agent, disclosed as a covalent inhibitor of TMPRSS2, was also evaluated. While dabigatran and rivaroxaban at 100 mu M concentration did not show any effect on SARS-CoV-2 infection, the virus preincubation with new guanidino-containing fXa-selective inhibitors 1 and 3 did decrease viral infectivity of VERO cells at subtoxic doses. When the cells were pre-incubated with 3, a reversible nanomolar inhibitor of fXa (K-i = 15 nM) showing the best in silico docking score toward TMPRSS2 (pdb 7MEQ), the SARS-CoV-2 infectivity was completely inhibited at 100 mu M (p < 0.0001), where the cytopathic effect was just about 10%. The inhibitory effects of 3 on SARS-CoV-2 infection was evident (ca. 30%) at lower concentrations (3-50 mu M). The covalent TMPRSS2 and the selective inhibitor nafamostat mesylate, although showing some effect (15-20% inhibition), did not achieve statistically significant activity against SARS-CoV-2 infection in the whole range of test concentrations (3-100 mu M). These findings suggest that direct inhibitors of the main serine proteases of the blood coagulation cascade may have potential in SARS-CoV-2 drug discovery. Furthermore, they prove that basic amidino-containing fXa inhibitors with a higher docking score towards TMPRSS2 may be considered hits for optimizing novel small molecules protecting guest cells from SARS-CoV-2 infection.

Published
2022

31. Detection and Genetic Characterization of Canine Adenoviruses, Circoviruses, and Novel Cycloviruses From Wild Carnivores in Italy

Author

Ndiana, Linda A., primary, Lanave, Gianvito, additional, Vasinioti, Violetta, additional, Desario, Costantina, additional, Martino, Camillo, additional, Colaianni, Maria Loredana, additional, Pellegrini, Francesco, additional, Camarda, Antonio, additional, Berjaoui, Shadia, additional, Sgroi, Giovanni, additional, Elia, Gabriella, additional, Pratelli, Annamaria, additional, Buono, Francesco, additional, Martella, Vito, additional, Buonavoglia, Canio, additional, and Decaro, Nicola, additional

Published
2022
Full Text
View/download PDF

33. Clinical and laboratory differences between pediatric hospitalized patients with sickle cell disease infected or not by SARS-CoV-2.

Author

Mafra Elia, Gabriella, Konstantyner, Tulio, Pilotto Nais, Rafaela, Augusto dos Santos, Andreia Regina, Angel, Andrea, and Pellegrini Braga, Josefina Aparecida

Subjects
*SICKLE cell anemia, *CHILD patients, *REVERSE transcriptase polymerase chain reaction, *HOSPITAL patients, *BLOOD cell count
Abstract

Objective: The aim of this study was to identify clinical and complete blood count differences between pediatric hospitalized patients with sickle cell disease infected or not by SARS-CoV-2 and compare the complete blood count of patients with sickle cell disease infected by SARS-CoV-2 before hospitalization and on admission. Methods: This study was a single-center prospective cohort. Data were collected from medical records of pediatric inpatients with sickle cell disease under 18 years old infected or not with SARS-CoV-2 from the first visit to the hospital until discharge and from the last medical appointment. All patients were tested for SARS-CoV-2 by the real-time reverse transcription polymerase chain reaction. Results: Among 57 pediatric patients with sickle cell disease hospitalized from March to November 2020 in a Brazilian academic hospital, 11 (19.3%) had a positive result for SARSCoV-2. Patients infected by SARS-CoV-2 had a higher prevalence of comorbidities than the ones who were not infected (63.6 vs. 30.4%; p=0.046). During hospital stay, no clinical or complete blood count differences between groups were found. There was a decrease in eosinophil count on hospital admission in patients with sickle cell disease infected by SARS-CoV-2 (p=0.008). Conclusions: Pediatric hospitalized patients with sickle cell disease infected by SARS-CoV-2 had more comorbidities and had a decrease in eosinophil count between hospital admission and the last medical appointment. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

37. Long‐term persistence of neutralizing SARS‐CoV‐2 antibodies in pets

Author

Decaro, Nicola, primary, Grassi, Andrea, additional, Lorusso, Eleonora, additional, Patterson, Edward I., additional, Lorusso, Alessio, additional, Desario, Costantina, additional, Anderson, Enyia R., additional, Vasinioti, Violetta, additional, Wastika, Christida E., additional, Hughes, Grant L., additional, Valleriani, Fabrizia, additional, Colitti, Barbara, additional, Ricci, Dominga, additional, Buonavoglia, Domenico, additional, Rosati, Sergio, additional, Cavaliere, Nicola, additional, Paltrinieri, Saverio, additional, Lauzi, Stefania, additional, Elia, Gabriella, additional, and Buonavoglia, Canio, additional

Published
2021
Full Text
View/download PDF

39. Long‐term persistence of neutralizing SARS‐CoV‐2 antibodies in pets.

Author

Decaro, Nicola, Grassi, Andrea, Lorusso, Eleonora, Patterson, Edward I., Lorusso, Alessio, Desario, Costantina, Anderson, Enyia R., Vasinioti, Violetta, Wastika, Christida E., Hughes, Grant L., Valleriani, Fabrizia, Colitti, Barbara, Ricci, Dominga, Buonavoglia, Domenico, Rosati, Sergio, Cavaliere, Nicola, Paltrinieri, Saverio, Lauzi, Stefania, Elia, Gabriella, and Buonavoglia, Canio

Subjects
SARS-CoV-2, VIRAL antibodies, PETS, IMMUNOGLOBULINS, DOGS
Abstract

We monitored the severe acute respiratory syndrome coronavirus 2 antibody response in seven dogs and two cats by using two multispecies ELISA tests, plaque reduction neutralisation test and virus neutralization. SARS‐CoV‐2 neutralizing antibodies in pets persisted up to 10 months since the first positive testing, thus replicating observations in COVID‐19 human patients. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

40. Do Dogs and Cats Passively Carry SARS-CoV-2 on Hair and Pads?

Author

Lauzi, Stefania, primary, Stranieri, Angelica, additional, Giordano, Alessia, additional, Lelli, Davide, additional, Elia, Gabriella, additional, Desario, Costantina, additional, Ratti, Gabriele, additional, Decaro, Nicola, additional, and Paltrinieri, Saverio, additional

Published
2021
Full Text
View/download PDF

48. Recombinant canine coronaviruses in dogs, Europe

Author

Decaro, Nicola, Mari, Viviana, Elia, Gabriella, Addie, Diane D., Camero, Michele, Lucente, Maria Stella, Martella, Vito, and Buonavoglia, Canio

Subjects
Gastroenteritis -- Health aspects -- Genetic aspects, Dogs -- Health aspects -- Genetic aspects, Infection -- Health aspects -- Genetic aspects, Health
Abstract

Coronaviruses (CoVs) (order Nidovirales, family Coronaviridae) are exceptionally prone to genetic evolution through accumulation of point mutations in genes encoding for structural and nonstructural proteins and homologous recombination among members [...]

Published
2010
Full Text
View/download PDF

49. Evaluation of Novel Guanidino-Containing Isonipecotamide Inhibitors of Blood Coagulation Factors against SARS-CoV-2 Virus Infection.

Author

Maio, Flavio De, Rullo, Mariagrazia, de Candia, Modesto, Purgatorio, Rosa, Lopopolo, Gianfranco, Santarelli, Giulia, Palmieri, Valentina, Papi, Massimiliano, Elia, Gabriella, De Candia, Erica, Sanguinetti, Maurizio, and Altomare, Cosimo Damiano

Subjects
VIRUS diseases, SARS-CoV-2, PROTEASE inhibitors, INTEGRASE inhibitors, SERINE proteinases, DRUG discovery, BLOOD coagulation factors, BLOOD coagulation
Abstract

Coagulation factor Xa (fXa) and thrombin (thr) are widely expressed in pulmonary tissues, where they may catalyze, together with the transmembrane serine protease 2 (TMPRSS2), the coronaviruses spike protein (SP) cleavage and activation, thus enhancing the SP binding to ACE2 and cell infection. In this study, we evaluate in vitro the ability of approved (i.e., dabigatran and rivaroxaban) and newly synthesized isonipecotamide-based reversible inhibitors of fXa/thr (cmpds 1–3) to hinder the SARS-CoV-2 infectivity of VERO cells. Nafamostat, which is a guanidine/amidine antithrombin and antiplasmin agent, disclosed as a covalent inhibitor of TMPRSS2, was also evaluated. While dabigatran and rivaroxaban at 100 μM concentration did not show any effect on SARS-CoV-2 infection, the virus preincubation with new guanidino-containing fXa-selective inhibitors 1 and 3 did decrease viral infectivity of VERO cells at subtoxic doses. When the cells were pre-incubated with 3, a reversible nanomolar inhibitor of fXa (Ki = 15 nM) showing the best in silico docking score toward TMPRSS2 (pdb 7MEQ), the SARS-CoV-2 infectivity was completely inhibited at 100 μM (p < 0.0001), where the cytopathic effect was just about 10%. The inhibitory effects of 3 on SARS-CoV-2 infection was evident (ca. 30%) at lower concentrations (3–50 μM). The covalent TMPRSS2 and the selective inhibitor nafamostat mesylate, although showing some effect (15–20% inhibition), did not achieve statistically significant activity against SARS-CoV-2 infection in the whole range of test concentrations (3–100 μM). These findings suggest that direct inhibitors of the main serine proteases of the blood coagulation cascade may have potential in SARS-CoV-2 drug discovery. Furthermore, they prove that basic amidino-containing fXa inhibitors with a higher docking score towards TMPRSS2 may be considered hits for optimizing novel small molecules protecting guest cells from SARS-CoV-2 infection. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results